



CASE PC/4-32514A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

HOLMES ET AL.

Examiner: Meghan Finn

APPLICATION NO: 10/516,633

FILED: JANUARY 19, 2005

FOR: THE USE OF SUBSTITUTED CYANOPYRROLIDINES AND
COMBINATION PREPARATIONS CONTAINING THEM FOR
TREATING HYPERLIPIDEMIA AND ASSOCIATED DISEASES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of June 11, 2008 has a shortened statutory time set to expire on July 11, 2008.
A one-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$120 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7831

Respectfully submitted,



Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36,134

Date: 8/1/08

08/05/2008 EFLORES 00000059 190134 10516633
01 FC:1251 120.00 DA



CASE PC/4-32514A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

HOLMES ET AL.

Examiner: Meghan Finn

APPLICATION NO: 10/516,633

FILED: JANUARY 19, 2005

FOR: THE USE OF SUBSTITUTED CYANOPYRROLIDINES AND
COMBINATION PREPARATIONS CONTAINING THEM FOR
TREATING HYPERLIPIDEMIA AND ASSOCIATED DISEASES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of June 11, 2008 has a shortened statutory time set to expire on July 11, 2008. A one-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$120 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7831

Respectfully submitted,



Gregory D. Ferraro
Attorney for Applicants
Reg. No. 36,134

Date:

8/1/08